Kailera Therapeutics Email Format

Biotechnology Research
51-200 employees
Waltham, MA, USA

Kailera Therapeutics is a biotechnology company developing clinical-stage injectable and oral therapies for the treatment of obesity and weight management.

Find contacts at Kailera Therapeutics

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@kailera.com

Company Overview

Industry
Biotechnology Research
Founded
2024
Headquarters
Waltham, MA, USA
Revenue
$25M-$50M
FUNDING Stage
Private
Key Executives
Ron Renaud (President & Chief Executive Officer), Doug Pagan (Chief Financial Officer), Paul Burgess (Chief Operating Officer & Chief Business Officer)

Tech Stack

Veeva Vault

CMS

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Kailera Therapeutics?

Kailera Therapeutics uses the first.last format, so Jane Smith would be jane.smith@kailera.com.

What is Kailera Therapeutics' lead clinical program in 2026?

Kailera Therapeutics' lead program is ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP receptor dual agonist currently in a global Phase 3 program called KaiNETIC, with data anticipated in 2028.

How many employees does Kailera Therapeutics have?

Kailera Therapeutics has approximately 151 employees. Tools like Clay can help you find and verify contact details for specific people at the company if you are building a prospect or partner outreach list.

Who leads Kailera Therapeutics as CEO?

Ron Renaud serves as President and Chief Executive Officer of Kailera Therapeutics, with Doug Pagan as CFO and Paul Burgess as Chief Operating Officer and Chief Business Officer rounding out the senior leadership team.

Where does Kailera Therapeutics source its pipeline compounds through its partnership with Hengrui?

Kailera Therapeutics in-licensed its pipeline through a strategic collaboration with Jiangsu Hengrui Pharmaceuticals, holding exclusive rights to develop and commercialize the compounds outside of China, Hong Kong, Macau, and Taiwan.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles